XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated statements of cash flows that sum to the total of the same such amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands):

 

 

 

Nine Months Ended September 30, 2024

 

 

Nine Months Ended September 30, 2023

 

 

 

Beginning of
period

 

 

End of
period

 

 

Beginning of
period

 

 

End of
period

 

Cash and cash equivalents

 

$

188,657

 

 

$

155,149

 

 

$

114,846

 

 

$

98,193

 

Restricted cash

 

 

5,770

 

 

 

8,770

 

 

 

5,770

 

 

 

5,770

 

Total cash, cash equivalents and restricted cash shown in
   the unaudited condensed consolidated statements of cash flows

 

$

194,427

 

 

$

163,919

 

 

$

120,616

 

 

$

103,963

 

Schedule of revenue consist of product sales to customers

The Company operates in one business segment. Results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues consist of net product sales to customers, all of which are sales in the U.S. Revenues by product are as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

NUPLAZID

 

$

159,186

 

 

$

144,828

 

 

$

446,518

 

 

$

405,308

 

DAYBUE

 

 

91,215

 

 

 

66,871

 

 

 

251,677

 

 

 

90,088

 

   Product sales, net

 

$

250,401

 

 

$

211,699

 

 

$

698,195

 

 

$

495,396